MedTrace Logo

REDUCE LAP-HF III Corvia Protocol 1701

NCT03191656 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2026-05-12

No results posted yet for this study

Summary

This is a post market trial to be conducted at sites in Germany. The device has CE approval in the EU. The purpose of this observational registry is to collect post market data in consecutive patients treated with the IASD System II, to further evaluate efficacy, safety and quality of life outcomes as a new treatment for patients with heart failure in a "real world" practice setting.

Conditions

Interventions

DEVICE

IASD Implant

Implantation of the IASD device using trans-septal puncture and the IASD system

Sponsors & Collaborators

  • Corvia Medical

    lead INDUSTRY

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-12
Primary Completion
2026-07-31
Completion
2028-07-31
FDA Device
Yes

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03191656 on ClinicalTrials.gov